Raymond James initiated coverage of Lenz Therapeutics with an Outperform rating and $37 price target. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on LENZ: Lenz Therapeutics files to sell 1.58M shares of common stock for holders Lenz Therapeutics reports Q2 EPS (40c), consensus (48c) Lenz Therapeutics submitted NDA for LNZ1000 Lenz Therapeutics initiated with a Buy at H.C. Wainwright LENZ Upcoming Earnings Report: What to Expect? Disclaimer & DisclosureReport an Issue
